Thank you for your interest in our clinical studies. Please select the study or studies in which you are interested in participating or learning more about. You may choose more than one study.
* must provide value
Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant Depression -This is a phase III, international, multi-centre, randomised, parallel group, fixed repeat dose, double-blind, controlled study. The study population will include participants aged ≥18 years with TRD. Overall, 568 participants are to be randomised in a 2:1:1 ratio to receive COMP360 25 mg, 10 mg or 1 mg. The study will last up to 16 weeks including a three- to ten-week Screening Period and six-week follow-up from investigational product (IP) administration. In this study, the aim is to assess the efficacy of COMP360, administered with psychological support in adult participants with TRD, in improving symptoms of depression. Click here for more information .
COMP006
Other Study Not Listed or Interested in Having Information on File for Future Studies
A Quadruple Masked, Dose-Finding Study to Evaluate the Efficacy and Safety of Intranasal BPL-003 in Patients with Treatment Resistant Depression - This is a Phase 2 study randomized, quadruple masked, multi-center study designed to investigate the efficacy and safety of a single dose of BPL-003 combined with psychological support in patients with treatment resistant depression (TRD). Participants are randomized 1:1:1 for a high, medium, or low single dose of BPL-003 with psychological support with follow-up visits for this 8-16 week study. Click here for more information. Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant Depression -This is a phase III, international, multi-centre, randomised, parallel group, fixed repeat dose, double-blind, controlled study. The study population will include participants aged ≥18 years with TRD. Overall, 568 participants are to be randomised in a 2:1:1 ratio to receive COMP360 25 mg, 10 mg or 1 mg. The study will last up to 16 weeks including a three- to ten-week Screening Period and six-week follow-up from investigational product (IP) administration. In this study, the aim is to assess the efficacy of COMP360, administered with psychological support in adult participants with TRD, in improving symptoms of depression. Click here for more information . Tianeptine for Treatment Resistant Depression(TRD) - study to determine if tianeptine is an effective antidepressant in patients who have failed two previous trials, to define the relationship between opioid signaling deficits and response to tianeptine treatment, and to develop a comprehensive assessment battery capable of identifying endogenous opioid signaling deficits to explore biological heterogeneity in the TRD population. Click here for more information . The CORAL STUDY -A Phase 3, Randomized, Double-Blind Study Comparing the Efficacy and Safety of the Investigational Drug Plus an Antidepressant Versus Placebo Plus an Antidepressant in Adults with Major Depressive Disorder (MDD) Click here for more information . Augmentation versus Switch: Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders with Treatment Resistant Depression (ASCERTAIN-TRD) - A randomized open-label trial investigating the effectiveness of aripiprazole augmentation, rTMS augmentation, or switching to venlafaxine XR or duloxetine. Click here for more information. Opiate Suicide Study in Patients With Major Depression - a research study to find out if the opioid properties of Ketamine are responsible for its antidepressant effects and if oral Buprenorphine will have an added benefit when taken for 4 weeks post infusion in Treatment Resistant Depression (TRD). Click here for more information . The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression (P-TRD) - A randomized study to determine the optimal therapeutic dose of Psilocybin in Treatment Resistant Depression (TRD). This study is open to participants with treatment resistant depression who are over 18. Click here for more information. Accelerated Theta Burst in Treatment-Resistant Depression (aTBS) - A treatment study evaluating an accelerated schedule of theta-burst stimulation using a transcranial magnetic stimulation device for treatment-resistant depression. Participants MUST be insured, be under the care of an established psychiatrist, and be on a stable dose of antidepressant medications that they will continue on for the duration of the study to be eligible for this study. Click here for more information. COMP005 Efficacy, Safety, and Tolerability of a Single Administration of COMP360 in Participants With Treatment Resistant Depression (TRD) - The main purpose of this study is to investigate how well one administration of COMP360 psilocybin works to lessen the severity of symptoms in TRD when administered with psychological support. The study will also be investigating the safety of COMP360 psilocybin, as well as how tolerable it is. This study is open to participants with treatment resistant depression who are over 18. Click here for more information. Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of BHV-7000 Monotherapy in Major Depressive Disorder - BHV-7000 is a drug that is being studied for for treating major depressive disorder. One way researchers think about depression is that it is caused by brain hyperactivity resulting from a combination of stress, genetics, and other environmental influences. This hyperactivity occurs on the level of the brain cells (neurons) which fire too frequently in hyperactive, depressed brains. BHV-7000 works through supporting activity of potassium channels along a part of our neurons that can stabilize hyperactivity and balance overall electrical activity of the brain. Click here for more information. COMP006
Other Study Not Listed or Interested in Having Information on File for Future Studies
Thank you for your interest in participating in our studies!
Please read through the brief descriptions of our current studies. This will walk you through the procedures that are involved so that you will have a complete understanding of the timeline. When you have finished reading the description, please continue to the online consent below. Acknowledgement of reading the study description does not obligate you to a particular study. This consent is only obtaining your permission to gather some basic health information. This basic information will assist us in determining eligibility for our studies. You must be at least 18 years of age to complete our online screening process.
The survey is given in two parts. The first survey will collect some basic demographic, medical, and psychiatric history, as well as assess current mood. The second survey will be emailed out after completion of the first and will collect some safety information and medication history.
After completion of the survey, we will contact you to inform you of your eligibility.
We look forward to discussing your eligibility shortly.
STUDY SCREENING CONSENT FORM
PROCEDURES
For this initial screening, with your permission, we would like to collect health information about you, including information about your general health (current mood states, family history, general medical conditions, medications, therapy, alcohol and substance use, height, weight, etc.) related to medical treatments and care you receive.
RISKS AND BENEFITS
There are no anticipated risks associated with this screening. You will not receive any direct benefit from participation. We cannot and do not guarantee or promise that you will receive any benefits from this screening.
TIME INVOLVEMENT
Your participation in this survey is self-timed, and usually takes anywhere from 30-60 minutes. Soon after completion (usually 1-2 weeks) we will contact you regarding your eligibility.
PAYMENTS
You will not be paid to complete this survey.
PARTICIPANT'S RIGHTS
If you have read this form and have decided to participate in this survey, please understand your participation is voluntary and you have the right to withdraw your consent or discontinue participation at any time without penalty or loss of benefits to which you are otherwise entitled.
The results of this screening may be presented at scientific or professional meetings or published in scientific journals. However, your identity will not be disclosed. You have the right to refuse to answer particular questions.